← All trials
NCT03751202
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 20, 2018
- Primary completion
- Dec 11, 2018
- Completion date
- Dec 11, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 34
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Respirent Pharmaceuticals Co Ltd.Lead sponsor
- BECRO Ltd.Collaborator
- BECRO Ltd.Overall official - principal investigator
- University of ThessalyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.